As policymakers search for potential cuts to the national budget, they risk jeopardizing the country’s most cost-effective use of healthcare dollars: biomedical innovation regarding vaccines , prescription drugs, and emerging therapies, including antibodies. As the nation rapidly ages, protecting this pipeline of medicine will not only improve health outcomes but will do so at a lower cost by reducing more expensive hospital and primary care.

This article first appeared on February 16th, 2023 on the American Telemedicine Association website. Despite the impressive advancements made by the health tech industry in recent years, access to care continues to burden populations in the United States. While care delivery across patient populations today is a complex, underlying systemic issue, there are opportunities to…

The OECD’s 23 February report Ready for the Next Crisis? Investing in Health System Resilience is as prescient as it is factual, adding to the long list of issues where the OECD performs critical analysis. It sets forth powerful ideas and shares valuable policy guidance with its member countries, which represent 63% of global GDP and 75% of world trade.

This article first appeared as part of The Los Angeles Times’ Golden State column FEB. 18, 2023 The very idea of a stress test can be stressful. On my way to my appointment a few days ago, I wondered what the test might reveal about my heart, and whether the drugs prescribed for a recent…

In the latest charge against the promise of healthy aging, Dr. Ezekiel Emanuel, oncologist and bioethicist, doubled down on his infamous 2014 essay stating that 75 is the ideal age to die. Now 65, he maintains that after age 75, he will no longer receive medical screenings and interventions like colonoscopies, cancer treatment, flu shots, and heart valve replacement.